Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 458 entries
Sorted by: Best Match Show Resources per page
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity.

Therapeutic advances in chronic disease

Crane J, McGowan B.
PMID: 26977279
Ther Adv Chronic Dis. 2016 Mar;7(2):92-107. doi: 10.1177/2040622315620180. Epub 2015 Dec 16.

There is a global obesity epidemic that will continue to be a financial burden on healthcare systems around the world. Tackling obesity through diet and exercise should always be the first intervention, but this has not proved to be...

Cite
Crane J, McGowan B. The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. Ther Adv Chronic Dis. 2015;7(2):92-107doi: 10.1177/2040622315620180.
Crane, J., & McGowan, B. (2016). The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. Therapeutic advances in chronic disease, 7(2), 92-107. https://doi.org/10.1177/2040622315620180
Crane, James, and McGowan, Barbara. "The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity." Therapeutic advances in chronic disease vol. 7,2 (2016): 92-107. doi: https://doi.org/10.1177/2040622315620180
Crane J, McGowan B. The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. Ther Adv Chronic Dis. 2016 Mar;7(2):92-107. doi: 10.1177/2040622315620180. Epub 2015 Dec 16. PMID: 26977279; PMCID: PMC4772342.
Copy Download .nbib Format: NLM
Opioid-induced constipation: advances and clinical guidance.

Therapeutic advances in chronic disease

Nelson AD, Camilleri M.
PMID: 26977281
Ther Adv Chronic Dis. 2016 Mar;7(2):121-34. doi: 10.1177/2040622315627801. Epub 2016 Jan 25.

Currently opioids are the most frequently used medications for chronic noncancer pain. Opioid-induced constipation is the most common adverse effect associated with prolonged use of opioids, having a major impact on quality of life. There is an increasing need...

Cite
Nelson AD, Camilleri M. Opioid-induced constipation: advances and clinical guidance. Ther Adv Chronic Dis. 2016;7(2):121-34doi: 10.1177/2040622315627801.
Nelson, A. D., & Camilleri, M. (2016). Opioid-induced constipation: advances and clinical guidance. Therapeutic advances in chronic disease, 7(2), 121-34. https://doi.org/10.1177/2040622315627801
Nelson, Alfred D, and Camilleri, Michael. "Opioid-induced constipation: advances and clinical guidance." Therapeutic advances in chronic disease vol. 7,2 (2016): 121-34. doi: https://doi.org/10.1177/2040622315627801
Nelson AD, Camilleri M. Opioid-induced constipation: advances and clinical guidance. Ther Adv Chronic Dis. 2016 Mar;7(2):121-34. doi: 10.1177/2040622315627801. Epub 2016 Jan 25. PMID: 26977281; PMCID: PMC4772344.
Copy Download .nbib Format: NLM
Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review.

Therapeutic advances in chronic disease

Peters J, Booth A, Peters R.
PMID: 26137206
Ther Adv Chronic Dis. 2015 Jul;6(4):160-9. doi: 10.1177/2040622315582353.

BACKGROUND: There is some evidence to suggest a possible association between calcium channel blocker (CCB) use and a lower decline in cognitive function compared with use of other hypertensive treatments. In particular, there is an emerging interest in the...

Cite
Peters J, Booth A, Peters R. Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review. Ther Adv Chronic Dis. 2015;6(4):160-9doi: 10.1177/2040622315582353.
Peters, J., Booth, A., & Peters, R. (2015). Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review. Therapeutic advances in chronic disease, 6(4), 160-9. https://doi.org/10.1177/2040622315582353
Peters, Jean, et al. "Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review." Therapeutic advances in chronic disease vol. 6,4 (2015): 160-9. doi: https://doi.org/10.1177/2040622315582353
Peters J, Booth A, Peters R. Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review. Ther Adv Chronic Dis. 2015 Jul;6(4):160-9. doi: 10.1177/2040622315582353. PMID: 26137206; PMCID: PMC4480546.
Copy Download .nbib Format: NLM
Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?.

Therapeutic advances in chronic disease

Field SK.
PMID: 26137207
Ther Adv Chronic Dis. 2015 Jul;6(4):170-84. doi: 10.1177/2040622315582325.

Acquired drug resistance by Mycobacterium tuberculosis (MTB) may result in treatment failure and death. Bedaquiline was recently approved for the treatment of multidrug-resistant tuberculosis (MDR-TB). This report examines the available data on this novel drug for the treatment of...

Cite
Field SK. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?. Ther Adv Chronic Dis. 2015;6(4):170-84doi: 10.1177/2040622315582325.
Field, S. K. (2015). Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?. Therapeutic advances in chronic disease, 6(4), 170-84. https://doi.org/10.1177/2040622315582325
Field, Stephen K. "Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?." Therapeutic advances in chronic disease vol. 6,4 (2015): 170-84. doi: https://doi.org/10.1177/2040622315582325
Field SK. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?. Ther Adv Chronic Dis. 2015 Jul;6(4):170-84. doi: 10.1177/2040622315582325. PMID: 26137207; PMCID: PMC4480545.
Copy Download .nbib Format: NLM
Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases.

Therapeutic advances in chronic disease

D'Ambrosio D, Freedman MS, Prinz J.
PMID: 26770667
Ther Adv Chronic Dis. 2016 Jan;7(1):18-33. doi: 10.1177/2040622315617354.

The first oral treatment for relapsing multiple sclerosis, the nonselective sphingosine-1-phosphate receptor (S1PR) modulator fingolimod, led to identification of a pivotal role of sphingosine-1-phosphate and one of its five known receptors, S1P1R, in regulation of lymphocyte trafficking in multiple...

Cite
D'Ambrosio D, Freedman MS, Prinz J. Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. Ther Adv Chronic Dis. 2016;7(1):18-33doi: 10.1177/2040622315617354.
D'Ambrosio, D., Freedman, M. S., & Prinz, J. (2016). Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. Therapeutic advances in chronic disease, 7(1), 18-33. https://doi.org/10.1177/2040622315617354
D'Ambrosio, Daniele, et al. "Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases." Therapeutic advances in chronic disease vol. 7,1 (2016): 18-33. doi: https://doi.org/10.1177/2040622315617354
D'Ambrosio D, Freedman MS, Prinz J. Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. Ther Adv Chronic Dis. 2016 Jan;7(1):18-33. doi: 10.1177/2040622315617354. PMID: 26770667; PMCID: PMC4707431.
Copy Download .nbib Format: NLM
H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes.

Therapeutic advances in chronic disease

Kutz C.
PMID: 27433309
Ther Adv Chronic Dis. 2016 Jul;7(4):190-7. doi: 10.1177/2040622316644481. Epub 2016 Jun 10.

BACKGROUND: Treatment of multiple sclerosis (MS) relapses can be complex in patients with concomitant diabetes. Corticosteroids and adrenocorticotropic hormones are known to cause alterations in glucose tolerance. Many patients have poor tolerability to therapy, necessitating alternative treatment options. Adrenocorticotropic...

Cite
Kutz C. H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes. Ther Adv Chronic Dis. 2016;7(4):190-7doi: 10.1177/2040622316644481.
Kutz, C. (2016). H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes. Therapeutic advances in chronic disease, 7(4), 190-7. https://doi.org/10.1177/2040622316644481
Kutz, Christen. "H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes." Therapeutic advances in chronic disease vol. 7,4 (2016): 190-7. doi: https://doi.org/10.1177/2040622316644481
Kutz C. H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes. Ther Adv Chronic Dis. 2016 Jul;7(4):190-7. doi: 10.1177/2040622316644481. Epub 2016 Jun 10. PMID: 27433309; PMCID: PMC4935834.
Copy Download .nbib Format: NLM
The diagnosis and treatment of chronic migraine: the case for daily scheduled opioid treatment in chronic headache.

Therapeutic advances in chronic disease

Derakhshan I.
PMID: 26568813
Ther Adv Chronic Dis. 2015 Nov;6(6):389. doi: 10.1177/2040622315608648.

No abstract available.

Cite
Derakhshan I. The diagnosis and treatment of chronic migraine: the case for daily scheduled opioid treatment in chronic headache. Ther Adv Chronic Dis. 2015;6(6):389doi: 10.1177/2040622315608648.
Derakhshan, I. (2015). The diagnosis and treatment of chronic migraine: the case for daily scheduled opioid treatment in chronic headache. Therapeutic advances in chronic disease, 6(6), 389. https://doi.org/10.1177/2040622315608648
Derakhshan, Iraj. "The diagnosis and treatment of chronic migraine: the case for daily scheduled opioid treatment in chronic headache." Therapeutic advances in chronic disease vol. 6,6 (2015): 389. doi: https://doi.org/10.1177/2040622315608648
Derakhshan I. The diagnosis and treatment of chronic migraine: the case for daily scheduled opioid treatment in chronic headache. Ther Adv Chronic Dis. 2015 Nov;6(6):389. doi: 10.1177/2040622315608648. PMID: 26568813; PMCID: PMC4622318.
Copy Download .nbib Format: NLM
Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.

Therapeutic advances in chronic disease

Iadarola ND, Niciu MJ, Richards EM, Vande Voort JL, Ballard ED, Lundin NB, Nugent AC, Machado-Vieira R, Zarate CA.
PMID: 25954495
Ther Adv Chronic Dis. 2015 May;6(3):97-114. doi: 10.1177/2040622315579059.

Current pharmacotherapies for major depressive disorder (MDD) and bipolar depression (BDep) have a distinct lag of onset that can generate great distress and impairment in patients. Furthermore, as demonstrated by several real-world effectiveness trials, their efficacy is limited. All...

Cite
Iadarola ND, Niciu MJ, Richards EM, et al. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis. 2015;6(3):97-114doi: 10.1177/2040622315579059.
Iadarola, N. D., Niciu, M. J., Richards, E. M., Vande Voort, J. L., Ballard, E. D., Lundin, N. B., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2015). Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Therapeutic advances in chronic disease, 6(3), 97-114. https://doi.org/10.1177/2040622315579059
Iadarola, Nicolas D, et al. "Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review." Therapeutic advances in chronic disease vol. 6,3 (2015): 97-114. doi: https://doi.org/10.1177/2040622315579059
Iadarola ND, Niciu MJ, Richards EM, Vande Voort JL, Ballard ED, Lundin NB, Nugent AC, Machado-Vieira R, Zarate CA. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis. 2015 May;6(3):97-114. doi: 10.1177/2040622315579059. PMID: 25954495; PMCID: PMC4416968.
Copy Download .nbib Format: NLM
The prevalence of vascular calcification in patients with end-stage renal disease on hemodialysis: a cross-sectional observational study.

Therapeutic advances in chronic disease

Kraus MA, Kalra PA, Hunter J, Menoyo J, Stankus N.
PMID: 25984289
Ther Adv Chronic Dis. 2015 May;6(3):84-96. doi: 10.1177/2040622315578654.

BACKGROUND: This multicenter international cross-sectional observational study characterized vascular and valvular calcification burden and correlations with pulse pressure, diabetes, hypertension, and cardiovascular diseases in prevalent hemodialysis patients.METHODS: We enrolled 275 consecutive adults with end-stage renal disease on maintenance hemodialysis...

Cite
Kraus MA, Kalra PA, Hunter J, et al. The prevalence of vascular calcification in patients with end-stage renal disease on hemodialysis: a cross-sectional observational study. Ther Adv Chronic Dis. 2015;6(3):84-96doi: 10.1177/2040622315578654.
Kraus, M. A., Kalra, P. A., Hunter, J., Menoyo, J., & Stankus, N. (2015). The prevalence of vascular calcification in patients with end-stage renal disease on hemodialysis: a cross-sectional observational study. Therapeutic advances in chronic disease, 6(3), 84-96. https://doi.org/10.1177/2040622315578654
Kraus, Mark A, et al. "The prevalence of vascular calcification in patients with end-stage renal disease on hemodialysis: a cross-sectional observational study." Therapeutic advances in chronic disease vol. 6,3 (2015): 84-96. doi: https://doi.org/10.1177/2040622315578654
Kraus MA, Kalra PA, Hunter J, Menoyo J, Stankus N. The prevalence of vascular calcification in patients with end-stage renal disease on hemodialysis: a cross-sectional observational study. Ther Adv Chronic Dis. 2015 May;6(3):84-96. doi: 10.1177/2040622315578654. PMID: 25984289; PMCID: PMC4416967.
Copy Download .nbib Format: NLM
Haemorrhoids: an update on management.

Therapeutic advances in chronic disease

Brown SR.
PMID: 28989595
Ther Adv Chronic Dis. 2017 Oct;8(10):141-147. doi: 10.1177/2040622317713957. Epub 2017 Jun 21.

Haemorrhoids are common, affecting up to one quarter of all adults according to some estimates. Numerous interventions exist for their management, ranging from topical and medical therapies to outpatient treatments and surgical interventions that aim to fix or excise....

Cite
Brown SR. Haemorrhoids: an update on management. Ther Adv Chronic Dis. 2017;8(10):141-147doi: 10.1177/2040622317713957.
Brown, S. R. (2017). Haemorrhoids: an update on management. Therapeutic advances in chronic disease, 8(10), 141-147. https://doi.org/10.1177/2040622317713957
Brown, Steven R. "Haemorrhoids: an update on management." Therapeutic advances in chronic disease vol. 8,10 (2017): 141-147. doi: https://doi.org/10.1177/2040622317713957
Brown SR. Haemorrhoids: an update on management. Ther Adv Chronic Dis. 2017 Oct;8(10):141-147. doi: 10.1177/2040622317713957. Epub 2017 Jun 21. PMID: 28989595; PMCID: PMC5624348.
Copy Download .nbib Format: NLM
The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the International Mood Disorders Collaborative Project.

Therapeutic advances in chronic disease

McIntyre RS, Woldeyohannes HO, Soczynska JK, Vinberg M, Cha DS, Lee Y, Gallaugher LA, Dale RS, Alsuwaidan MT, Mansur RB, Muzina DJ, Carvalho A, Kennedy S.
PMID: 27347362
Ther Adv Chronic Dis. 2016 May;7(3):153-9. doi: 10.1177/2040622315627805. Epub 2016 Feb 01.

OBJECTIVES: The aim of the study was to evaluate the prevalence of and illness characteristics in adults with major depressive disorder (MDD) with anxious distress specifier (ADS) enrolled in the International Mood Disorders Collaborative Project, which is a collaborative...

Cite
McIntyre RS, Woldeyohannes HO, Soczynska JK, et al. The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the International Mood Disorders Collaborative Project. Ther Adv Chronic Dis. 2016;7(3):153-9doi: 10.1177/2040622315627805.
McIntyre, R. S., Woldeyohannes, H. O., Soczynska, J. K., Vinberg, M., Cha, D. S., Lee, Y., Gallaugher, L. A., Dale, R. S., Alsuwaidan, M. T., Mansur, R. B., Muzina, D. J., Carvalho, A., & Kennedy, S. (2016). The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the International Mood Disorders Collaborative Project. Therapeutic advances in chronic disease, 7(3), 153-9. https://doi.org/10.1177/2040622315627805
McIntyre, Roger S, et al. "The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the International Mood Disorders Collaborative Project." Therapeutic advances in chronic disease vol. 7,3 (2016): 153-9. doi: https://doi.org/10.1177/2040622315627805
McIntyre RS, Woldeyohannes HO, Soczynska JK, Vinberg M, Cha DS, Lee Y, Gallaugher LA, Dale RS, Alsuwaidan MT, Mansur RB, Muzina DJ, Carvalho A, Kennedy S. The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the International Mood Disorders Collaborative Project. Ther Adv Chronic Dis. 2016 May;7(3):153-9. doi: 10.1177/2040622315627805. Epub 2016 Feb 01. PMID: 27347362; PMCID: PMC4907069.
Copy Download .nbib Format: NLM
Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus.

Therapeutic advances in chronic disease

Atkin S, Javed Z, Fulcher G.
PMID: 26568812
Ther Adv Chronic Dis. 2015 Nov;6(6):375-88. doi: 10.1177/2040622315608646.

Patients with type 2 diabetes mellitus require insulin as disease progresses to attain or maintain glycaemic targets. Basal insulin is commonly prescribed initially, alone or with one or more rapid-acting prandial insulin doses, to limit mealtime glucose excursions (a...

Cite
Atkin S, Javed Z, Fulcher G. Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus. Ther Adv Chronic Dis. 2015;6(6):375-88doi: 10.1177/2040622315608646.
Atkin, S., Javed, Z., & Fulcher, G. (2015). Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus. Therapeutic advances in chronic disease, 6(6), 375-88. https://doi.org/10.1177/2040622315608646
Atkin, Stephen, et al. "Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus." Therapeutic advances in chronic disease vol. 6,6 (2015): 375-88. doi: https://doi.org/10.1177/2040622315608646
Atkin S, Javed Z, Fulcher G. Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus. Ther Adv Chronic Dis. 2015 Nov;6(6):375-88. doi: 10.1177/2040622315608646. PMID: 26568812; PMCID: PMC4622316.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 458 entries